These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18507334)

  • 1. [Advances in the study of molecular mechanisms, applications and screening for altered peptide ligand].
    Wang QQ; Yang HZ; Hu ZW
    Yao Xue Xue Bao; 2008 Feb; 43(2):113-7. PubMed ID: 18507334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
    Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
    J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific immunomodulation via altered peptide ligands.
    Bielekova B; Martin R
    J Mol Med (Berl); 2001 Oct; 79(10):552-65. PubMed ID: 11692152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
    Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
    Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
    Denkberg G; Reiter Y
    Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy.
    Kinnunen T; Jutila K; Kwok WW; Rytkönen-Nissinen M; Immonen A; Saarelainen S; Närvänen A; Taivainen A; Virtanen T
    J Allergy Clin Immunol; 2007 Apr; 119(4):965-72. PubMed ID: 17335888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing cytotoxic T cell responses with altered-peptide ligands.
    Zhao R; Collins EJ
    Arch Immunol Ther Exp (Warsz); 2001; 49(4):271-7. PubMed ID: 11726029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
    Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands.
    Crawford F; Jordan KR; Stadinski B; Wang Y; Huseby E; Marrack P; Slansky JE; Kappler JW
    Immunol Rev; 2006 Apr; 210():156-70. PubMed ID: 16623770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage-displayed libraries of peptide/major histocompatibility complexes.
    Dogan I; Dorgham K; Chang HC; Parizot C; Lemaître F; Ferradini L; Reinherz EL; Debré P; Gorochov G
    Eur J Immunol; 2004 Feb; 34(2):598-607. PubMed ID: 14768065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor.
    Peng KW; Holler PD; Orr BA; Kranz DM; Russell SJ
    Gene Ther; 2004 Aug; 11(15):1234-9. PubMed ID: 15215883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [TCR peptide vaccination for autoimmune diseases: involvement of T-T interaction between autoimmune T cells presenting TCR peptide and CD4-CD8- regulatory T cells].
    Yamamura T
    Nihon Rinsho; 1997 Jun; 55(6):1519-24. PubMed ID: 9200942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the activity of partially agonistic MHC:peptide ligands dependent on the quality of immunological help?
    Uhlin M; Masucci M; Levitsky V
    Scand J Immunol; 2006 Dec; 64(6):581-7. PubMed ID: 17083613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of peptide/MHC-induced TCR downregulation: deciphering the triggering kinetics.
    Utzny C; Coombs D; Müller S; Valitutti S
    Cell Biochem Biophys; 2006; 46(2):101-11. PubMed ID: 17012752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recognition of HLA-peptide complexes by T cell receptor].
    Nishimura Y
    Arerugi; 1999 Oct; 48(10):1144-7. PubMed ID: 10554399
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantifying the strength of ligand antagonism in TCR triggering.
    Van Den Berg HA; Burroughs NJ; Rand DA
    Bull Math Biol; 2002 Jul; 64(4):781-808. PubMed ID: 12216421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Discovery of MHC restriction in antigen recognition of T cells].
    Lan GT; Zhu LP; Zhang W
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Oct; 24(5):539-41. PubMed ID: 12905783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of modulation of T cell responses by N-palmitoylated peptides.
    Bueno C; Lee KK; Chau LA; Lee-Chan E; Singh B; Strejan GH; Madrenas J
    Eur J Immunol; 2004 Dec; 34(12):3497-507. PubMed ID: 15495162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues.
    Shang X; Wang L; Niu W; Meng G; Fu X; Ni B; Lin Z; Yang Z; Chen X; Wu Y
    Eur J Immunol; 2009 Aug; 39(8):2248-58. PubMed ID: 19593772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.